DAGLB抗体;DAGLB Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P13235(DAGLB Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The DAGLB (diacylglycerol lipase beta) antibody is a research tool designed to study the enzyme diacylglycerol lipase-beta, a key player in the endocannabinoid system. DAGLB catalyzes the hydrolysis of diacylglycerol (DAG) to produce 2-arachidonoylglycerol (2-AG), one of the most abundant endogenous cannabinoids. 2-AG acts as a lipid signaling molecule, binding to cannabinoid receptors (CB1 and CB2) to regulate synaptic plasticity, inflammation, pain perception, and metabolic processes.

DAGLB is a membrane-associated enzyme predominantly expressed in the central nervous system, immune cells, and peripheral tissues. Its structure includes a transmembrane domain and a conserved serine hydrolase catalytic site, distinguishing it from its isoform DAGLA (alpha). Dysregulation of DAGLB activity or expression has been implicated in neurological disorders (e.g., epilepsy, neurodegeneration), metabolic syndromes, and cancer progression.

Antibodies targeting DAGLB are critical for detecting protein expression, localization, and quantification in experimental models (e.g., Western blot, immunohistochemistry). They help elucidate DAGLB's role in physiological and pathological contexts, particularly its interaction with lipid metabolism pathways and therapeutic potential in modulating endocannabinoid signaling. Validation of these antibodies often includes knockout controls to ensure specificity, given the structural similarities within the lipase family.